At Silence, our vision is to transform peoples’ lives around the world by silencing diseases through our precision engineered medicines and driving positive change for the communities around us.

Our investigational product candidates harness the body's natural mechanism of RNA interference (RNAi) to precisely target and silence disease-associated genes.

Learn How Gene Silencing Works

Our Clinical Trials

We are currently conducting clinical trials for cardiovascular disease due to high levels of lipoprotein(a), or Lp(a), and rare iron-loading anemia conditions, thalassemia and myelodysplastic syndrome, or MDS.


Learn More About the APOLLO Phase 1 Clinical Program for Cardiovascular Disease Due to High Lp(a)

Learn more

Learn More About the GEMINI II Phase 1 Clinical Program for Thalassemia and MDS

Learn more

To support better understanding of the diseases we are currently researching, we have developed a series of ‘eBooks’ to provide an overview of their impact and current management approaches.

Patient Resources

Please see below for links to support organizations for those affected by high Lp(a), thalassemia and MDS.


Individuals with familial hypercholesterolemia (FH) are more likely to have high Lp(a) levels than the general population. For this reason, patient groups focused on FH, such as FH Europe, and FH Foundation provide information on elevated Lp(a) and are increasingly involved in raising awareness of the condition.

For a list of supporting organizations across Europe, please visit this link.


The Thalassaemia International Federation (TIF) has a wealth of resources and provides links to local organizations around the world, to help you find support in your own country.


Organisations such as MDS UK Patient Support group, AAMDS and the MDS Foundation offer a wide variety of materials in English language.

Further international organizations can be found on this website.